mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) are focal malformations of cortical development (FMCDs) that are highly associated with intractable epilepsy. TSC and FCD are mTORopathies caused by a spectrum of pathogenic variants in the mechanistic target of rapamycin (mTOR) pathway genes leading to differential activation of mTOR signaling. However, whether the degree of mTOR hyperactivity influences disease severity remains unclear. Here, we examined the effects of differential mTOR hyperactivity levels on epilepsy and associated neuropathology in a mouse model of TSC and FCD. Constitutively active Rheb (Rheb CA), the canonical activator of mTOR complex 1 (mTORC1), was expressed in mouse embryos of either sex via in utero electroporation at low, intermediate, and high concentrations to induce different mTORC1 activity levels in developing cortical neurons. We found that Rheb CA expression induced mTORC1 hyperactivation and increased neuronal soma size and misplacement in a dose-dependent manner. No seizures were detected in the low Rheb CA mice, whereas the intermediate and high Rheb CA mice displayed spontaneous, recurrent seizures that significantly increased with higher Rheb CA concentrations. Seizures were associated with a global increase in microglial activation that was notably higher in the regions containing Rheb CA-expressing neurons. These data demonstrate that neuronal mTOR hyperactivity levels influence the severity of epilepsy and associated neuropathology in experimental TSC and FCD. Overall, these findings highlight the importance of evaluating the outcome of individual variants on mTOR activity levels and support personalized medicine strategies based on patient variants and mTOR activity level for TSC, FCD, and potentially other mTORopathies. SIGNIFICANCE STATEMENT Tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) are epileptogenic cortical malformations caused by pathogenic variants in mechanistic target of rapamycin (mTOR) pathway genes leading to differential mTOR hyperactivation. Here, we present novel findings that neuronal mTOR hyperactivity levels correlate with the severity of epilepsy and associated neuropathology in a mouse model of TSC and FCD. Our findings suggest the need to evaluate the outcome of individual variants on mTOR activity levels in clinical assessments and support personalized medicine strategies based on patient variants and mTOR activity level. Additionally, we present useful modifications to a previously described mouse model of TSC and FCD that allows for titration of seizure frequency and generation of a mild to severe epilepsy phenotype as applicable for preclinical drug testing and mechanistic studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
Kettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00011.2010 · Cited by 3,547 · cited 1×
“Activated microglia undergo morphological changes from small cell bodies with ramified (branched) processes to enlarged cell bodies with long or short, thickened processes or ameboidshaped cells with no processes (Kettenmann et al., 2011).”
BackgroundFrench, J. A., Lawson, J. A., Yapici, Z., Ikeda, H., Polster, T., Nabbout, R., Curatolo, P., de Vries, P. J., Dlugos, D. J., Berkowitz, N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31419-2 · Cited by 764
Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2
Tavazoie, S. F., Alvarez, V. A., Ridenour, D. A., Kwiatkowski, D. J., & Sabatini, B. L. (2005) · Nature Neuroscience · doi:10.1038/nn1566 · Cited by 497 · cited 1×
“Because mTORC1 hyperactivation causes neuronal hypertrophy (Kwon et al., 2003; Tavazoie et al., 2005; Kassai et al., 2014), we also measured the soma size of GFP electroporated neurons as a proxy for mTORC1 activity.”
BackgroundPark, S. M., Lim, J. S., Ramakrishina, S., Kim, S. H., Kim, W. K., Lee, J., Kang, H.-C., Reiter, J. F., Kim, D. S., Kim, H. (., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.05.039 · Cited by 114
Kassai, H., Sugaya, Y., Noda, S., Nakao, K., Maeda, T., Kano, M., & Aiba, A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.048 · Cited by 107 · cited 3×
“mTOR hyperactivation in the developing cortex causes neuronal hypertrophy and abnormal neuronal migration leading to cortical dyslamination (Feliciano et al., 2011; Kassai et al., 2014; Tsai et al., 2014; Hsieh et al., 2016; Lin et al., 2016).”
BackgroundRalA Functions as an Indispensable Signal Mediator for the Nutrient-sensing System
Maehama, T., Tanaka, M., Nishina, H., Murakami, M., Kanaho, Y., & Hanada, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805822200 · Cited by 80 · cited 1×
“…pCAG-GFP (Addgene, catalog #11150; 4.8 g/ l) or pCAG-GFP (1–3 g/ l) pCAG-Rheb CA (also known as pCAG-Rheb S16H; gift from T. Maehama and K. Hanada; Maehama et al., 2008, 1.5, 2.5, or 3.5 g/ l) together with 0.03% Fast Green dye (for visualizing injection) was injected (1–1.5 l) into the right…”
MethodInfluential
Cited by
mTOR and neuroinflammation in epilepsy: implications for disease progression and treatment
Ravizza, T., Scheper, M., Di Sapia, R., Gorter, J., Aronica, E., & Vezzani, A. (2024) · Nature Reviews Neuroscience · doi:10.1038/s41583-024-00805-1 · Cited by 141
“This imbalance between excitatory and inhibitory processes was evident at the molecular, cellular, circuit and network levels in both preclinical models and human tissue studies of mTORopathies 6,8,148–150 .”
Iffland, P. H., Carson, V., Bordey, A., & Crino, P. B. (2019) · Epilepsia · doi:10.1111/epi.16370 · Cited by 84
Self-citationEpileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy
Aronica, E., Specchio, N., Luinenburg, M. J., & Curatolo, P. (2023) · Brain · doi:10.1093/brain/awad048 · Cited by 74
Specchio, N., Nabbout, R., Aronica, E., Auvin, S., Benvenuto, A., de Palma, L., Feucht, M., Jansen, F., Kotulska, K., Sarnat, H., et al. (2023) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2023.08.005 · Cited by 58
Zimmer, T. S., Broekaart, D. W. M., Gruber, V.-E., van Vliet, E. A., Mühlebner, A., & Aronica, E. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.01028 · Cited by 48
“(73) observed that mTOR hyperactivity resulted in a global increase in Iba1-positive microglia that were both larger and had a more activated morphology.”
Metadata
- Authors
- Nguyen, L. H., Mahadeo, T., & Bordey, A.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2019-01-30
- Volume
- 39
- Issue
- 14
- Pages
- 2762-2773
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2913672248
- Cited by
- 126
- References
- 7
- FWCI
- 8.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia. https://app.cochat.ai/papers/10.1523/jneurosci.2260-18.2019
- The paper
- Nguyen, L. H., Mahadeo, T., & Bordey, A. (2019). mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia. The Journal of Neuroscience. https://doi.org/10.1523/jneurosci.2260-18.2019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.